Vampire Bats & Rabies: A Potential New Threat | Boehringer Ingelheim US Vampire Bats & Rabies: A Potential New Threat | Boehringer Ingelheim US Read more on the emerging threat of rabid vampire bats in the Southern US. Helping prevent this disease preserves the lives of livestock worldwide.
How to Apply How to Apply To apply for the program, please complete one of the following application forms and follow the directions on the application form submission
Update on LUME-Meso Clinical Trial Update on LUME-Meso Clinical Trial Click here to read an update on the LUME-Meso clinical trial, comparing nintedanib with other treatment options for malignant pleural mesothelioma.
New Analyses Further Add to the Efficacy and Safety Profile of OFEV® (nintedanib) in Idiopathic Pulmonary Fibrosis (IPF) New Analyses Further Add to the Efficacy and Safety Profile of OFEV® (nintedanib) in Idiopathic Pulmonary Fibrosis (IPF) New Analyses Further Add to the Efficacy and Safety Profile of OFEV® (nintedanib) in Idiopathic Pulmonary Fibrosis (IPF)
FDA Provides Full Approval to Praxbind, Specific Reversal Agent for Pradaxa FDA Provides Full Approval to Praxbind, Specific Reversal Agent for Pradaxa FDA Provides Full Approval to Praxbind, Specific Reversal Agent for Pradaxa
Cyltezo®, First Interchangeable Biosimilar to Humira®, Receives Preferred Formulary Status with Optum Rx for Commercially Insured Patients Cyltezo®, First Interchangeable Biosimilar to Humira®, Receives Preferred Formulary Status with Optum Rx for Commercially Insured Patients Cyltezo®, First Interchangeable Biosimilar to Humira®, Receives Preferred Formulary Status with Optum Rx for Commercially Insured Patients
A future without pills – could AI change the way we treat psychiatric diseases? A future without pills – could AI change the way we treat psychiatric diseases? Dr Cornelia Dorner-Ciossek talks about how her work with smartphone tech could transform how we treat mental illness.
Ivermectin in Animal Health products and COVID-19 Ivermectin in Animal Health products and COVID-19 Ivermectin in Animal Health products and COVID-19
Spesolimab prevented generalized pustular psoriasis flares in Effisayil™ 2 trial Spesolimab prevented generalized pustular psoriasis flares in Effisayil™ 2 trial Spesolimab prevented generalized pustular psoriasis flares in Effisayil™ 2 trial
Cyltezo®, first and only FDA-approved Interchangeable biosimilar to Humira®, now commercially available in the U.S. Cyltezo®, first and only FDA-approved Interchangeable biosimilar to Humira®, now commercially available in the U.S. Cyltezo®, first and only FDA-approved Interchangeable biosimilar to Humira®, now commercially available in the U.S.
New Analyses Showed Consistent Efficacy of OFEV® (nintedanib) Across Various Patient Populations with Idiopathic Pulmonary Fibrosis (IPF) New Analyses Showed Consistent Efficacy of OFEV® (nintedanib) Across Various Patient Populations with Idiopathic Pulmonary Fibrosis (IPF) New Analyses Showed Consistent Efficacy of OFEV® (nintedanib) Across Various Patient Populations with Idiopathic Pulmonary Fibrosis (IPF)
FDA approves treatment option for T2D in children 10 and older FDA approves treatment option for T2D in children 10 and older FDA has approved Jardiance® (empagliflozin) tablets to lower blood sugar along with diet and exercise in children 10 years and older with type 2 diabetes. See Safety, PI & Med Guide.
Boehringer Ingelheim Animal Health Joins Coalition Calling for Greater Broadband Access in Rural Areas Boehringer Ingelheim Animal Health Joins Coalition Calling for Greater Broadband Access in Rural Areas Boehringer Ingelheim Animal Health Joins Coalition Calling for Greater Broadband Access in Rural Areas
Sant Cugat del Vallès (Barcelona) Sant Cugat del Vallès (Barcelona) Boehringer Ingelheim settled in Spain in 1952. For almost 70 years, t
Shelter Revamps Make for Strong Bonds, More Adoptions Shelter Revamps Make for Strong Bonds, More Adoptions Shelter Revamps Make for Strong Bonds, More Adoptions
Results announced from EMPACT-MI phase III trial Results announced from EMPACT-MI phase III trial Results announced from EMPACT-MI phase III trial in adults following a heart attack.
Sustainable cattle production: Feeding the world while minimizing environmental effect Sustainable cattle production: Feeding the world while minimizing environmental effect Sustainable cattle production: Feeding the world while minimizing environmental effect
U.S. FDA Grants Breakthrough Therapy Designation for Spesolimab for the Prevention of Flares in Adults with Generalized Pustular Psoriasis (GPP) U.S. FDA Grants Breakthrough Therapy Designation for Spesolimab for the Prevention of Flares in Adults with Generalized Pustular Psoriasis (GPP) U.S. FDA Grants Breakthrough Therapy Designation for Spesolimab for the Prevention of Flares in Adults with Generalized Pustular Psoriasis (GPP)
J-Code Issued for SPEVIGO J-Code Issued for SPEVIGO Boehringer Ingelheim receives permanent J-code for SPEVIGO, indicated for the treatment of generalized pustular psoriasis flares in adults
US FDA approves the Cyltezo® Pen, a new autoinjector option, ahead of July 1 commercial launch US FDA approves the Cyltezo® Pen, a new autoinjector option, ahead of July 1 commercial launch US FDA approves the Cyltezo® Pen, a new autoinjector option, ahead of July 1 commercial launch
Boehringer Ingelheim Partners with Thoeris to Investigate a Novel Approach to Treat Urea Cycle Disorders Boehringer Ingelheim Partners with Thoeris to Investigate a Novel Approach to Treat Urea Cycle Disorders Boehringer Ingelheim Partners with Thoeris to Investigate a Novel Approach to Treat Urea Cycle Disorders
Arising Vaccines to Help Zoo Elephants | Boehringer Ingelheim US Arising Vaccines to Help Zoo Elephants | Boehringer Ingelheim US Find out how Boehringer Ingelheim is developing vaccines to help North African zoo elephants suffering from deadly infections and illness.
Niha Agarwalla Niha Agarwalla My career challenge at Boehringer Ingelheim by Niha Agarwalla. Read it now!
Boehringer Ingelheim announces nintedanib expanded access program (EAP) for children and adolescents with fibrosing interstitial lung disease Boehringer Ingelheim announces nintedanib expanded access program (EAP) for children and adolescents with fibrosing interstitial lung disease Boehringer Ingelheim announces nintedanib expanded access program (EAP) for children and adolescents with fibrosing interstitial lung disease
Boehringer Shows Support for Children with Skin Conditions Boehringer Shows Support for Children with Skin Conditions This year, Boehringer Ingelheim joined campers at Camp Discovery in Millville, PA to demonstrate its support for those facing chronic skin conditions.